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“The first step is to establish that something is possible; then probability will occur.” 





Precision medicine constitutes an emerging strategy that aims at the individualization 
of healthcare by considering the personal molecular features and environmental 
factors of the patient in question. Genetic biomarkers constitute one dimension of a 
patient’s molecular phenotype that can allow for treatment stratification. As such, 
incorporating genetic variability into clinical decision making has raised great interest 
with drug developers, regulators and in the wider medical community. Importantly 
however, most studies that evaluated associations of genetic variability with drug 
reponse or toxicity interrogated only selected, mostly common candidate variants and 
the prevalence and relevance of rare variants for pharmacogenetics remained largely 
unexplored. This thesis demonstrates how population-scale Next-Generation 
Sequencing (NGS) data can be leveraged to map the interindividual and 
ethnogeographic variability of genes with medical importance.  
Papers I and II focused on ATP-binding casette (ABC) transporters, as an example 
of a pharmacogenetically relevant gene family, and show how their variability can have 
potential predictive value in breast cancer chemotherpy. The human ABC transporter 
family consists of 48 functionally important membrane proteins which mediate the 
active transport of a plethora of substrates, including a multitude of endogenous 
substrates as well as drugs, such as calcium channel blockers and various 
chemotherapeutics. Because of this physiological and clinical importance, Paper I 
systematically investigated the interindividual and ethnogeographic variability in the 
ABC transporter superfamily using NGS data of 138,632 unrelated individuals 
worldwide, and used an list of sophisticated computational algorithms to estimate their 
functional relevance. In total, 62,793 exonic variants were discovered, of which 98.5% 
were rare with minor allele frequencies (MAF) <1.5%. Based on these data, individuals 
were found to harbor between 9.3 and 13.9 deleterious ABC variants, only 0.3% of 
which were shared among all populations. As such, this work analyzed the landscape 
of ABC transporter variability on an unprecedented scale and revealed large 
interindividual and ethnogeographic variability with potential relevance for the 
treatment with ABC transporter substrates. 
Paper II built on these findings by evaluating whether ABC transporter variability was 
associated with drug response. As drug resistance due to facilitated ABC transporter-
mediated efflux of chemotherapeutics constitutes an important cause of morbidity and 
mortality, ABC transporter variability was evaluated whether it could predict treatment 
outcomes in breast invasive carcinoma (BRCA), clear cell renal carcinoma (ccRCC) 
and hepatocellular carcinoma (HCC). In contrast to previous studies, these analyses 
did not only consider common ABC polymorphisms but considered also rare genetic 
variants using mutational burden testing. Importantly, variant burden of ABCC1 was 
found to significantly assoiate with reduced survival in BRCA patients, specifically in 
those subgroups treated with the MRP1 (the transporter encoded by ABCC1) 
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substrates doxorubicin (p=0.0088) and cyclophosphamide (p=0.0011). In contrast, no 
association was discovered in tamoxifen-treated patients (p=0.13). Multiple variants 
enriched in the high mutational burden group affected residues in functionally 
important transporter domains providing additional mechanistic support. Combined, 
these results argue for a model in which multiple variants with individually small effect 
sizes shape drug resistance, thus incentivizing a shift in strategy away from the 
interrogation of candidate variants and towards the incorporation of germline data for 
precision cancer medicine.  
Paper III indicated how publically available sequencing data from individuals can be 
used to provide accurate estimates of population-specific carrier rates and genetic 
complexity of 450 human autosomal recessive (AR) diseases. Specifically, population-
scale NGS data of individuals free from clinically diagnosed congenital disorders was 
used to identify disease allele carrier frequencies for 450 AR disorders. Using 85 
diseases with known epidemiology, the data showed that our prevalence estimates 
corresponded well to clinically reported incidences (p<0.001; R=0.68). Furthermore, 
these data allowed for the first time to evaluate the genetic complexity of the human 
AR diseasome and estimate population-specific founder effects. As such, these 
analyses reveal the molecular genetics of AR diseases with unprecedented resolution 
and provide important insights into epidemiology, complexity and population-specific 
founder effects, which can provide a powerful resource for clinical geneticists to inform 
population-adjusted genetic screening programs, particularly in otherwise 
understudied ethnogeographic groups.  
In conclusion, by utilizing sophisticated computational methods for the analysis of 
publically available population-scale sequencing data of >130,000 individuals, this 
thesis uncovered the landscape of genetic variability in genes with importance for 
pharmacogenetics and congenital disease. The resulting findings aspire to improve 
pharmacogenetic interpretations and carrier screening programs and, hopefully, can 
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Precision medicine describes a medical model that aims at the personalization of 
treatment, including the selection of therapeutic modalities and regimens, by taking 
genomic, proteomic and metabolomic signatures of the individual patient into account. 
Particularly genetic biomarkers have received great attention from the medical 
community in pursuit of precision medicine because they are inherently stable and 
relatively easy to probe. Particularly, precision genomic medicine has emerged in the 
fields of pharmacogenomics and genetic disease diagnostics [1].  
 
However, commonly identified genetic candidate variants can only explain a small 
portion of the entirety of hereditary phenotypes. The remaining missing heritability 
constitutes a major problem in explaining genotype-phenotype association, and 
impedes the development of translational genetics for precision medicine. Therefore, 
this thesis evaluates the signature of rare genetic variability in pharmacogenetic and 
disease-associated genes and whether the consideration of such rare and often 
neglected variants using computational tools can improve prediction models and, 
eventually, facilitate precision medicine. 
 
Specifically, the work is focused on two areas of genomic medicine, 
pharmacogenomics and genetic diseases: 
 
Pharmacogenomics 
It is estimated that 25%-50% of drug treatments do not result in the intended response 
or cause adverse events [2], 20-30% of which can be explained by genetic factors. 
Importantly however, twin studies suggest that commonly considered polymorphisms 
can only explain 30-40% of the heritable inter-individual differences in drug disposition 
[2]. For instance, up to 89% of caffeine pharmacokinetics were heritable after 
correcting for effects of smoking and hormonal contraceptives; however, only 8% of 
these differences were attributed to common variants in CYP1A2 [3]. Similarly, the 
vast majority of metoprolol and torsemide pharmacokinetics variability is heritable, 
whereas known variants in genes implicated in their disposition explain only 2%-39% 
of this variance [4]. These results suggest that other genetic factors beyond the 







Missing heritability is also relevant for our understanding of and screening for genetic 
disease. For instance, the commonly interrogated pathogenic variants in ABCA4 can 
only explain 83.6% of the heritability of ABCA4-associated retinal dystrophy [5]. 
Similarly, the recommended carrier screening program by the American College of 
Obstetricians and Gynecologists (ACOG) and the American College of Medical 
Geneticists (ACMG) for cystic fibrosis (CF), comprising the 23 most common CFTR 
variants, only identifies around 80% of CF cases [6]. Combined, these data suggest 
that commonly considered well-characterized candidate single nucleotide 
polymorphisms (SNPs) can only explain a part of the heritable disease risk.  
 
What explains the missing heritability? Evan Eichler and colleagues [7] suggested 
contributions of multiple factors:  
1) Effects of gene-environment interactions rather than of genetic factors alone. 
2) Epigenetics may contribute to the inheritance of phenotypes of interest. 
3) Genetic variants interact with other biomolecules to affect protein expression.  
4) Genetic variants of interest in unexplored genomic regions. 
5) Effects of rare variants. 
 
Apart from the missing heritability, another challenge in the development of precision 
genomic medicine is the population bias in current genomic research databases and 
references, which impairs the understanding of human diseases and aggravates 
healthcare imbalances in minority populations [8]. For instance, the GWAS Catalog, 
containing 35 million samples from 2,511 studies, is constituted predominantly of 
individuals of European descent (81%) and only 14% of Asian descent and 5% from 
rest populations worldwide [9]. Similar disparity of population composition is observed 
in the Allele Frequency Aggregator database 
(https://www.ncbi.nlm.nih.gov/snp/docs/gsr/alfa/) and GTEx, of which 84% and 85% 
of the included individuals are of European descendent, respectively [10]. This 
disproportionate population makeup of the databases and references may impede 
analyses of the genetic disease aetiology and complicate treatment stratifications for 
most non-European populations. As only one example, CYP2D6*10, an allele impairs 
the enzyme activity and reportedly associated with toxicity of risperidone [11], is 
harboured by 70% of Asians yet <10% in worldwide other populations [12]. The vast 
difference of clinical important allele frequencies among populations indicate that 
population-tailored pharmacogenetic testing programs may be more efficient than if 
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they were based on global guidelines. Combined, the biased genomic sampling can 
impair the implementation of precision medicine in specific populations. 
 
This PhD thesis aims to extend pharmacogenetic and genetic disease analyses 
beyond the analyses of commonly interrogated genetic variants by incorporating 
comprehensive genomic profiles based on population-scale Next-Generation 
Sequencing (NGS) data. In the following sections, I will provide information about how 
NGS technology has revolutionized human genomics, depict the trajectory of human 
NGS projects and illustrate their application for precision medicine.  
 
1.1 SEQUENCING TECHNOLOGIES 
1.1.1 First generation sequencing 
First generation sequencing refers Sanger sequencing and Maxam-Gilbert 
sequencing [13]. Sanger method employs dideoxynucleotides to terminate chain and 
determine the sequence. Sanger sequencing is highly robust and was the standard 
genomic approach before the advent of NGS for three decades. Despite the accuracy, 
sanger sequencing generates low throughputs and is costly and time-consuming. 
Combined, sanger sequencing gradually becomes as a means of validation rather 
than an explorative method for biological question of interest in general. 
 
1.1.2 Second generation sequencing 
Since the early 21st century, sequencing technologies have developed rapidly. 
Compared to first generation sequencing, these new technologies feature higher 
throughput and sensitivity, as well as broader genomic coverage [14–17]. Second 
generation sequencing, often referred to as NGS technologies, were specifically 
developed for genetic, epigenetic and gene expression research across a wide range 
of biological applications. Among these, whole exome sequencing (WES) and whole 
genome sequencing (WGS) are two common utilized NGS techniques in genome 
research. WGS is capable of decoding the sequence of the entire genome while WES 
only focuses on variants in the protein-coding region, covering only approximately 
1.5% of the whole genome [18].  
 
Importantly, NGS mostly generate short reads (< 1 kb) [19]. Short-read data is overall 
accurate, can sequence loci with high depth and is supported by a multitude of 
bioinformatics tools [13,20], which has resulted in short-read NGS becoming the 
current standard tool in sequencing-based clinical diagnostics [21]. However, this 
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method has limited sequencing accuracy for repetitive sequences [22] or regions with 
high genomic complexity, including regions with high GC content, structural variations 
or highly homologous nearby genes [22]. These problems are of particular importance 
for pharmacogenomics, as a multitude of clinically relevant genes are genetically 
complex, including CYP2D6, CYP2B6 and various HLA genes. 
 
1.1.3 Third generation sequencing 
To overcome these limitations, long-read sequencing, often referred to as third 
generation sequencing, has been developed, which is capable of generating reads of 
many kbs in length [23]. These technologies facilitate the interrogation of loci that are 
inaccessible by conventional short read sequencing [22]. The leading two platforms 
comprise single molecule real-time (SMRT) and nanopore sequencing [20]. Both 
methods increase the genetic coverage of sequencing and mapping accuracy in 
difficult sequences and allow single molecule haplotype profiling [24]. These technical 
advantages have facilitate the clinical diagnosis of a variety of diseases, such as 
Huntington’s disease [25] and Fragile X syndrome [21]. Similarly, the technology 
demonstrates other potential clinical utility by precisely promotes the variant and 
haplotype interpretation of drug toxicity related genes such as HLA genes and 
CYP2D6 [26]. Additionally, it’s also anticipated that the technology will have a dramatic 
impact of variant interpretation of population sequencing projects [24]. Main 
disadvantages of third generation sequencing include high cost, high requirement for 
expensive materials and immature bioinformatics support [24]. 
 
1.2 EVOLUTION OF HUMAN SEQUENCING PROJECTS 
1.2.1 Human Genome Project 
The Human Genome Project (HGP) was initiated in 1990 and finished in 2003 with 
the aim to decode the entire human genome. Overall, the HGP covered >99% gene-
containing regions of the human genome with >99% sequencing accuracy. The 
project completed with a human reference genome comprising 2.85 billion nucleotides 
and estimated approximately 20,000-25,000 protein-coding genes across the human 
genome [27]. This therefore lay a substantial foundation for biomedical and medical 
research. 
 
1.2.2 The 1000 Genome Project 
Following the reference genome, the 1000 Genome Project was initiated to investigate 
the genotypic diversity across worldwide populations [28]. The project overall included 
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2,504 individuals from 5 superpopulations subdivided into 26 well-defined 
subpopulations, and provided allele frequency and haplotype information for a total of 
84.7 million SNPs and 36.7 million indels. The project demonstrated for the first time 










1.2.3 Exome Aggregation Consortium (ExAC) and The Genome Aggregation 
Database (gnomAD)  
While the 1000 Genomes Project analyzed well defined populations, the overall cohort 
size was relatively small and as such not suitable to adequately capture rare genetic 
variants. Therefore, the Exome Aggregation Consortium (ExAC) formed with the goal 
to unify available sequencing data from a variety of projects into one central database 
that eventually contained exome sequences of 60,706 individuals [30]. Due to the 
increased number of individuals, this dataset provided an improved resource for the 
analysis of rare genetic variability with relatively high resolution. 
 
Fig 2. Population composition of gnomAD cohort. (Reprinted from [31]) 
 
Fig 1. Number of variant sites of each subpopulation individual in 




ExAC was further extended to include increasing numbers of WGS data in the form of 
The Genome Aggregation Database (gnomAD) with substantially enlarged cohort size 
to 141,456 individuals (Fig. 2), including 12,487 Africans, 17,720 Latinos, 5,185 
Ashkenazi Jews, 9,977 East Asians, 64,603 non-Fin Europeans, 12,562 Finns and 
15,308 South Asians [31]. Furthermore, the latest gnomAD version (v3) additionally 
included genomic information of the Amish, as an important founder population. 
  
The project overall identified 14.9 and 229.9 million high-confidence variants for 
exome and genome datasets, respectively, as well as 433,371 structural variations 
[32]. Among these, 443,769 variants lead to frameshifts, stop gain and splicing site 
disruption across the human genome using stringent filtering criteria, suggesting the 
genome-wide existence of putative loss-of-function (LOF) variants [31]. Additionally, 
gnomAD estimated the LOF intolerance of each gene by calculating the ratio of the 
number of observed pLOF variants to the number of statistically expected pLOF 
variants (O/E). These genes with lower O/E value tend to be intolerant to pLOF 
variants and align with genes, the mutations of which are known to result in Mendelian 
disorders (Fig. 3). Taken together, gnomAD constitutes a reliable large-scale resource 














1.3 BIOMEDICAL APPLICATIONS OF SEQUENCING DATA 
1.3.1 Pharmacogenomics 
1.3.1.1 Introduction into pharmacogenomics 
Up to 15% of EMA-approved and 264 FDA-approved medicines contain 
pharmacogenomic information in their labels, 7% of which are clinically actionable, 
affecting 18% of all drug prescriptions in the US [34–36] (Fig. 4). The main goal of 
pharmacogenomics is to identify how the genetic makeup of an individual impacts 
drug pharmacokinetics, response or toxicity of drugs. For instance, carriers of the 
HLA-B*57:01 allele are at risk to develop abacavir hypersensitivity syndrome, whereas 
non-carriers are completely protected. As a consequence of this discovery, 
preemptive pharmacogenetic testing for HLA-B*57:01 is compulsory before abacavir 
prescription. Similarly, rs4363657 in the SLCO1B1 gene, encoding the OATP1B1  
 
simvastatin transporter, has been identified as a strong predictor of simvastatin-
induced myopathy with odds ratio of 17.4 in variant homozygotes [37], and these 
findings have resulted in the abolishment of high dose prescriptions of simvastatin 
throughout Europe. Nowadays, more pharmacogenetic tests are available if the 
prescribing physician wants to evaluate the pharmacogenetic risk of potential toxicity 
preemptively. The testing is most commonly utilized in the pharmacological treatment 
of depression, anxiety, lipid disorders and hypertension, however, interestingly, the 




Fig 4. Drug/prescription classification according to actionable germline 




1.3.1.2 Pharmacogenetic testing in cancer chemotherapy                                    
One major arena of pharmacogenetic testing is the support of clinical decision-making 
in cancer chemotherapy. Notable examples are genotyping of DPYD, UGT1A1 and 
TPMT for the guidance of fluoropyrimidine, irinotecan and mercaptopurine 
prescriptions. For DPYD, the most extensively studied variant *2A (rs3918290, splice 
donor) as well as others [39–41], have been reported to significantly reduce 
dihydropyrimidine dehydrogenase activity, resulting in reduced fluoropyrimidine 
detoxification and increased risk of life-threatening toxicity. Based on these findings, 
the preemptive testing of functionally relevant DPYD variability is recommended when 
considering treating colon cancer patients with fluoropyrimidines in the Netherlands. 
Similarly, genotype-guided prescribing following preemptive testing of TPMT variants 
can reduce the risk of thioguanine toxicity [42]. In addition, UGT1A1*28 homozygotes 
are poor metabolizers of irinotecan and at increased risk to develop severe toxicity 
after treatment [43], resulting in the US FDA recommending irinotecan dose reductions 
for UGT1A1*28 carriers. 
 
1.3.1.3 ABC polymorphism in cancer treatment 
While the aforementioned genetic variants constitute strong predictors of drug-specific 
toxicity, drug resistance constitutes arguably an even larger problem in clinical 
oncology. Despite the dramatic progress of the industry of next generation anticancer 
drug development, 90% of patients are primarily resistant or acquire resistance during 
cancer chemotherapy [44], which is the major cause to the treatment failure. Common 
resistance mechanisms include drug efflux, change of drug targets, limited drug 
activation or facilitated drug inactivation [45]. 
Excessive drug efflux causing chemotherapy resistance is primarily contributed by 
ATP-binding cassette (ABC) transporter superfamily (Fig. 5), pumping the drug 
substrates into intracellular or extracellular space in an ATP-dependent manner [46]. 
The human ABC superfamily consists of 48 functional ABC transporters attributed to 
8 subfamilies and 22 pseudogenes [46,48], of which 12 have been found to mediate 
the transport of chemotherapeutic drugs [49], of which the MDR1-encoding ABCB1, 
MRP1-encoding ABCC1,and BCRP-encoding ABCG2 are the most comprehensively 
studied ABC transporters in cancer chemotherapy to date. ABC transporters are 
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widely expressed in liver, placenta, kidney, blood-testis barrier and blood-brain barrier 
in mammals [46].  
 
Genetic variants of ABC transporters reportedly can affect substrate transport activity 
in vitro. For instance, the synonymous variant I1145I of ABCB1 affects cotranslational 
folding of MDR1 through the introduced rare codon, resulting in reduced levels of 
functional transporter [50]. Clinically, genetic variants of at least 12 ABC transporters 
reportedly significantly associated with drug response and toxicity in cancer medicine. 
ABCB, ABCC and ABCG subfamilies were most extensively investigated ABC 
subfamilies while ABCAs and others are scarcely found pharmacogenetic 
associations. Specifically, rs1128503, rs2032582 and rs1045642 of ABCB1 are so far 
the most extensively investigated variants and discovered affect the drug response or 
toxicity for of chemotherapy for at least 7 cancers.  
 
Fig 5. ABC transporter related multidrug resistance mechanism. Increased expression 
of certain ABC transporters will increase the pump-out of compound from cytoplasm. The reduced 
drug concentration inside the cell will therefore decreased the toxicity and response simultaneously. 




Importantly, rare variants with MAF < 1%, rather than above mentioned common 
variants, occupy the vast majority (92.9%) of genetic variations of pharmacogenes 
(Fig. 6) [51]. Nevertheless, rare variants conventionally draw little attention to medical 
community due to the low 
prevalence and cost-effectiveness 
of research funding. In addition, 
rare genetic variants reportedly 
contribute 30-40% of 
pharmacogenetic functionality 
variability. More detailed analyses 
of other pharmacogene families 
have revealed the abundance of 
rare variants and their functional 
importance in CYPs [52], SLC [53] 
and SLCO transporters [54]. These 
evidences together suggest that 
rare variants can be of importance 
for understanding the interpersonal variability of ABC transporter activity in the era of 
precision medicine. In contrast, most studies only focused on a limited set of ABC 
common variants and analyzed only relatively small cohorts with unclear population 
definition [55–58]. Such study designs decrease the statistical power and hinders the 
clinical interpretation of ABC transporter variability in worldwide diverse populations.  
 
1.3.2 Pathogenic variants underlying genetic diseases 
1.3.2.1 Introduction into congenital disease genetics 
It is estimated that individuals are up to 99.9% genetically identical, with only 
approximately one variation every 1,000 bases between individuals [59]. Among 
variant classes, SNPs are most abundant accounting for approximately 90% of human 
genetic variation [60]. Apart from SNPs, genetic variants include indels and structural 
variants. Indels are defined as small insertions or deletions with size < 1kb [61] and 
are of widespread molecular and phenotypic importance [62,63]. Furthermore, several 
indels constitute well-characterized causes of Mendelian disorders, including CF [64], 
Fragile X syndrome [65] and Huntington's disease. Likewise, a multitude of larger 
structural variants defined as  >1kb [61] can underlie the molecular pathogenesis of 
genetic disease, including Hunter syndrome, Williams-Beuren syndrome and Sotos 
syndrome [66–68]. In general, the protein-coding region variants are generally 
considered as more clinically relevant than intronic variants. 
 
 
Fig 6. Variant composition of pharmacogenes 
by MAF. (Reprinted from [51]) 
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Virtually all variants causing congenital diseases are rare, commonly defined as 
MAF<1%, whereas common variants have been mostly implicated in complex disease 
risk, for instance in type 2 diabetes or schizophrenia [69]. Notably however, such 
common variants have generally low effect size [70]. In contrast, rare genetic variants 
often have larger effect size, as shown for instance for type 1 diabetes and Alzheimer’s 
disease [71,72], as well as for hypercholesterolaemia and nonsyndromic hearing loss 
[73,74].  
 
1.3.2.2 Carrier screening of autosomal recessive disorders 
Autosomal recessive (AR) disorders are genetic diseases that result from 
homozygosity  or compound heterozygosity of pathogenic variations. To date, more 
than 2,000 AR disorders have been identified worldwide [75] with 3 per 1,000 
neonates being affected by AR disorders recessive disorders globally [76] and around 
approximately 35% individuals are carrier for at least one Mendelian disorder [77]. 
Notably, this incidence can be even substantially higher in communities that are 
genetically isolated, such as Ashkenazi Jews or Old Order Amish, or populations 
where consanguinity is common [78,79]. 
 
Carrier screening aims to identify if clinically asymptomatic persons are carriers of 
pathogenic variants [80]. This information can thus facilitate genetic reproductive 
counselling and thereby contribute substantially to public health.  
 
1.3.2.2.1 Carrier screening for monogenic autosomal recessive disorders 
The carrier screening program was initially implemented in specific ethnogeographic 
groups with high risk of genetic disease [81,82]. A well-known example is the carrier 
screening program that was firstly introduced in the Jewish community in the 1970s 
with an attempt to reduce cases of Tay-Sachs disease [83]. Another typical example 
is the carrier screening program for β-thalassaemia, initially launched in 
Mediterranean countries and the Middle East where the disease is more prevalent and 
screening has become mandatory in Iran and Saudi Arabia [84]. These screening 
programs were highly successful and reduced incidence of Tay-Sachs disease and β-
thalassemia in the respective groups by 80-90% [83,85].In contrast, The ACOG has 
recommend the genetic testing of CF, spinal muscular atrophy and sickle cell disease 
for across populations. Additional population-specific carrier screening programs 
include testing for carriers of Bloom syndrome, Gaucher disease Type I, and Canavan 
disease in Ashkenazi Jews [86].  
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As most population-based carrier screening programs are implemented in high-risk 
communities, this population-tailored strategy may fail to identify the risk of AR 
disorders at other ethnical groups due to differences in disease allele composition. For 
instance, up to 12% of newborn cases of sickle cell diseases are ethnically from the 
low-risk populations in California [87]. For example, CFTR, the gene whose disruption 
is causative for CF, is highly polymorphic with more than 2,000 variants that have been 
described. Importantly however, frequencies of the majority of these vary drastically 
among worldwide populations [31]. For instance, the ΔF508 mutation accounts for 70% 
of CF causative variants in Caucasian CF patients [88], whereas it only explains <30% 
of cases in African populations [89]. As a consequence, optimal pathogenic variant 
panels may differ vastly between populations and therefore hamper the predictive 
performance of current screening programs. Additionally, a substantial fraction of the 
AR disorder cases fail to be detected by the currently establish screening programs, 
as evidenced by the fact that only 80% of CF cases can be accounted for by screening 
panel recommended by ACMG and ACOG [6]. 
 
1.3.2.2.2 Expanded carrier screening programs 
Conventional genetic screening programs only focus on a small selection of specific 
genetic diseases. However, the vast majority of rare genetic diseases is not covered 
in these panels, resulting in false negative assessments and underestimated disease 
risk [90]. Importantly, the advent of NGS facilitates allows for the first time to 
systematically screen for pathogenic variants of multiple genetic diseases across 
genome. Expanded carrier screening has therefore emerged in which hundreds of 
rare disorders are probed in addition to those monogenic disorders already included 
in conventional screening programs. Such a strategy was found to be cost-effective 
compared to screening programs focused on individual candidate variants [81,90]. 
Until 2017, at least 16 providers offered expanded carrier screening that meets 
analytical requirements, testing between 41 and 1,792 conditions [91]. The included 
conditions cover not only monogenic disorders but also provide guidance for the 
consideration of cognitive disability status and clinical interventions [92]. However, the 
genetic pathogenicity of approximately 50% of rare diseases remains to be elucidated 





2.1 GENERAL AIM 
The overarching aim of this PhD project is to leverage population-scale sequencing 
data to facilitate precision medicine, specifically by discovering how genetic variability 
can serve as biomarker for treatment stratification and guide genetic screening 
programs.  
 
2.2 STUDY-SPECIFIC AIMS 




Unravel the genetic landscape of the human ABC transporter superfamily and its 
ethnogeographic variability.     
 
Paper II: 



















3 MAIN METHODS 
3.1 NGS DATA OF POPULATION SEQUENCING PROJECTS 
In Paper I-III, 138,632 individuals’ NGS data of worldwide seven ethnic groups, whose 
ancestry constitutes Africans, Latinos, Ashkenazi Jewish, East Asians, South Asians, 
Finnish, non-Fin Europeans, were accessed from gnomAD [31]. These data are 
publicly available and there is neither publication nor use limitation. 
 
3.2 NGS DATA OF CANCER GENOME SEQUENCING PROJECT 
In Paper II, breast invasive carcinoma (BRCA), cell renal carcinoma (ccRCC) and liver 
hepatocellular carcinoma (HCC) were studied as they are among most common 
cancers reported. WGS data of peripheral and bulk tumor-adjacent healthy tissue from 
these cancer patients were accessed from the The Cancer Genome Atlas (TCGA) 
database for germline genetic variant analysis, with granted ethical permit from US 
National Institutes of Health. The corresponding clinical data were downloaded from 
the TCGA Pan-Cancer Clinical Data Resource [94]. The variant calling was performed 
with GATK v4.1 according to the best practice workflow [95,96]. 
 
3.3 VARIANT EFFECT PREDICTION  
In Paper I-III, functionality of missense variants was predicted with a variety of best 
performed algorithms evaluated by Li et al [97]. In Paper III exclusively, variant 
pathogenicity was firstly annotated with ClinVar [98]. Additionally, the pathogenicity of 
the frameshift, splicing site, stop gained and start lost variants was predicted using 
LOFTEE plugin (https://github.com/konradjk/loftee) of Variant Effect Predictor [99]. 
 
3.4 DISEASE INCIDENCE ESTIMATION AND GENETIC COMPLEXITY 
In Paper III, disease-gene associations were identified from the Online Mendelian 
Inheritance in Man (OMIM) database [75]. Genetic incidences of AR disorders were 
estimated as 𝑞2 where q denotes the aggregated MAF of pathogenic variants of the 
causative gene(s) of each disorder. Additionally, 90% Jeffrey’s confidence interval (CI) 
was calculated for putatively genetic incidence of each AR disorder using “ratesci” 
from R [100]. The genetic complexity of each studied disorder was evaluated by 
informedness index, calculated as I = maxv (D(v) - P(v)) where v stands for an array 
of the MAF-sorted interrogated variants. The D(v) denotes the fraction of the disease 
whose molecular pathogenesis is the interrogated variants included v, while P(v) 
denotes the percentage of variant number of v to number of identified all pathogenic 
variants in a given disorder. 
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3.5 TERTIARY STRUCTURE ANALYSIS 
Papers I and II systematically investigated the potential variant effect by mapping the 
variant on protein tertiary structures. The experimentally determined structures were 
accessed from Protein Data Bank (https://www.rcsb.org/) [101], while others were 
either from literature or modelled using Phyre2 [102]. PyMOL (v2.1.1) was employed 
for genetic variability visualization on the functional domains. 
 
3.6 STATISTICS 
In Paper II, best cutoff of variant burden among the cancer cohort were optimized with 
conditional inference tree using “partykit” package in R [103], while the potential 
dichotomization effect was examined with linear tail-restricted cubic spline modeling 
implemented in R “rms” package [104]. Associations between single variants and 
variant burden were identified with linear-by-linear association tests in R package 
“coin” [105]. The survival difference of different groups was computed using log-rank 


















4 RESULTS AND DISCUSSION 
4.1 PAPER I: ETHNOGEOGRAPHIC AND INTERINDIVIDUAL VARIABILITY OF 
HUMAN ABC TRANSPORTERS 
Human ABC transporters mediate a spectrum of endogenous substrates such as 
peptides and sugars. Furthermore, ABC transporters translocate a spectrum of drug 
substrates, including HIV protease inhibitors and chemotherapy agents. Genetic 
polymorphisms in ABC genes can modulate the risk for inappropriate drug response 
or toxicity, and can underlie a variety of genetic diseases [106–109]. While the 
importance of ABC variants has been well recognized, previous studies focused 
almost exclusively on a few candidate polymorphisms and information on the overall 
profile of ABC variability had been lacking. 
 
4.1.1 Interindividual differences in ABC transporter variability and their 
functional implications  
Paper I analyzed the landscape and profile of genetic variability in the human ABC 
transporter superfamily. Across all 48 ABC transporters encoded in the human 
genome, 37,467 genetic variants were identified that impacted on protein primary 
structure, which included missense (n=33,340), splice site (n=924), indels (n=435), 
frameshifts (n=1,549), as well as variants resulting in the loss of the canonical start 
codon or the gain of a premature stop codon (n=1,219). 
 
Of these variants, 19,309 variants were estimated to be deleterious and 17,524 
missense variants were predicted as neutral by 5 state-of-the-art algorithms (Fig. 7A). 
Highest deleterious variant burden was in ABCA13 (n=1,183), ABCA7 (n=953) and 
ABCA4 (n=865), while the least deleterious variants were discovered in ABCB7 (n=43) 
and ABCE1 (n=60; Fig. 7B). Importantly, the vast majority of putatively deleterious 
variants were found to be rare with MAF < 1% (19,266 out of 19,309; 99.7%). On 
average, individuals harbored most variants with functional consequences in ABCB5 
(n=1.8) and ABCB1 (n=1.1; Fig. 7C). Of these, rs2032582, a variant reportedly 
associated with altered drug response and toxicity in different contexts of cancer 
chemotherapy [55,110,111], accounted for 80% of the functional genetic variability of 
ABCB1. By contrast, 24 of 48 ABC transporters harbored no common variants with 
putative functional relevance and the entire functional genetic variability was attributed 
to rare variations. Taken together, each individual was estimated to harbor on average 
9.8 deleterious ABC variations of which 21% were owing to rare genetic variants (Fig. 
7D). These findings were similar to other highly polymorphic gene classes, such as 
the SLC [53] and SLCO [54] transporter families, suggesting potentially important roles 




Fig 7. ABC functional genetic variability. A, Overview of variant functionality prediction. B, 
Results of functionality prediction of each ABC gene. C, Number of individual harbored ABC 
deleterious variants and corresponding contribution by rare genetic variability. D, Estimated 
deleterious variant burden of ABC variants per individual. 
 
4.1.2 Ethnogeographic variability within the ABC transporter superfamily 
Notably, 76% of the functional genetic variability was attributed to variants that were 
exclusively found in a single population, of which ABCA7 and ABCE1 harbored the 
lowest (70%) and highest (92%) fraction of population-specific variants, respectively 
(Fig. 8A-C). Vast majority of these population-specific variants were found in 
Europeans (n=6,815) and South Asians (n=2,413) whereas Finns (n=368) and Jews 
(n=136) were the least population-specific, likely at least in part due to the 
disproportionally large number of Europeans in the available data set. In contrast, only 




Fig 8. Population-specificity of putatively deleterious variants. A, Percentage of 
population-specific and shared variants. B, Distribution of population-specific deleterious 
variants in each component population. C, Population-specificity of deleterious variants of 
each ABC gene. D, Estimated deleterious variant burden of ABC variants per individual of 
each population. E, Estimated overall ABC variant burden per individual of each population. 
 
Largest difference of each population was observed in ABCA10 with each African 
supposedly harboring 2.4 putatively deleterious variants contrast to 0.3 variants in 
Europeans (Fig. 8D). Other significant interethnic differences were found in ABCC11 
(1.8 putatively deleterious variants observed in East Asians contrast to 0.5 in Africans), 
ABCB1 (1.4 variants observed in South Asians contrast to 0.2 in Africans) and ABCG2 
(1.3 observed in East Asians contrast to 0.1 in Europeans). On the contrary, ABCE1, 
ABCFs and ABCDs harboured the least putatively deleterious variants and, 
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consequently, the lowest differences across populations. Across the entire gene 
superfamily, Africans harboured most putatively deleterious ABC variants (n=13.9 
deleterious variants per individual) while the lowest numbers were predicted in South 
Asians (n=9.3; Fig. 8E). These results together revealed the extensive population-
specificity of ABC genetic functional variability, and incentivized the use of population-
specific strategies to profile ABC variability. 
 
4.1.3 Conclusions 
Paper I investigated the worldwide genetic variability of the ABC transporter 
superfamily using NGS data of >130,000 worldwide unrelated individuals. These 
analyses revealed that individuals harboured on average 9.3 to 13.9 putatively 
deleterious ABC transporter variants across the different populations, 21% of which 
were allotted to rare genetic variants and 76% of which were population-specific. As 
such, the study unveiled the drastic inter-individual and populational differences of 
















4.2 PAPER II: GERMLINE VARIANT BURDEN IN MULTIDRUG RESISTANCE 
TRANSPORTERS IS A THERAPY-SPECIFIC PREDICTOR OF SURVIVAL 
IN BREAST CANCER PATIENTS 
Drug resistance constitutes the main clinical issue in oncology, accounting for 
approximately 90% anticancer treatment failures [44]. ABC transporter-mediated drug 
efflux is one important mechanism of chemotherapy resistance. ABCB1, ABCC1 and 
ABCG2 encode the most relevant multi-drug resistance transporters MDR1, MRP1 
and BCRP, respectively. A limited number of ABC germline variants have been found 
related with altered drug response or toxicity across a range of cancers [110–112]. 
However, most studies used small heterogenous cohorts and, likely as a consequence, 
the identified associations commonly failed to replicate and results between studies 
were often conflicting. Furthermore, due to the focus on single variant associations, 
no study addressed the predictive value of the rare genetic variability in these genes. 
 
4.2.1 Variant burden of ABC transporters predicts cancer prognosis 
Germline variant and outcome data from the TCGA database were leveraged to 
evaluate whether ABC transporter variability can predict the prognosis of cancer 
patients. Common, previously reported variations were firstly examined that whether 
they could explain therapeutic outcomes using disease-specific survival (DSS) as a 
proxy. Notably however, none of the analysed common variations was associated with 
DSS. It was then hypothesized that drug resistance might be due to combinatorial 
effects of multiple variations with individually small effect sizes and thus shifted from 
a variant centric to a mutational burden model. To this end, permutation tests were 
employed to evaluate the power of variant burden cut-offs, while log-rank tests were 
employed for comparing DSS in high and low variant burden groups. 
 
High variant burden of ABCC1 correlated with significantly reduced DSS in BRCA 
patients (HR=3.22; 95%CI=[1.62-6.4]; log-rank p=0.00043, permutation p=0.031; Fig. 
9). Furthermore, moderate associations were identified for ABCB1 variability and 
decreased survival in ccRCC patients (HR=1.83, 95%CI=[1.0-3.37], log-rank p=0.047, 
permutation p=0.13), as well as for variant burden in ABCC1 and increased DSS in 





Fig 9. The impact of variant burden of multidrug resistance related ABC transporters 














4.2.2 Predictive value of ABC gene variant burden is drug-specific 
Importantly, when these analyses were stratified by therapeutic regimen, it 
demonstrated strong drug-specific associations, providing additional mechanistic 
support (Table 1). Specifically, variant burden of ABCC1 strongly predicted survival in 
the subgroup of BRCA patients treated with cyclophosphamide (HR=9.22, 
95%CI=[1.83-46.36], log-rank p=0.0011) and doxorubicin (HR=4.57, 95%CI=[1.31-
15.93], log-rank p=0.0088), two cytotoxic MRP1 substrates [113], whereas no 
significant association was found for tamoxifen-treated patients (log-rank p=0.13), a 
selective estrogen receptor modulator that inhibits the expression of estrogen 
response genes in the breast and is not known to be significantly transported by MRP1.  
 
Table 1: Effect of variant burden of ABCB1, ABCC1 and ABCG2 on cancer DSS based 
on TCGA cohort. 
 















































































* The references of the HRs were defined as low variant groups. 
 
 




4.2.3 ABC variants potentially associated with drug-specific resistance 
localize to functionally important transporter domains 
MRP1 (encoded by ABCC1) consists of two transmembrane domains (TMDs) 
containing one nucleotide-binding domain (NBD) each (Fig. 10A). Of the 34 ABCC1 
variants potentially associated with drug-specific resistance, multiple encoded amino 
acid locates in functionally important domains. The variants encode G231C and 
R230Q are situated inside the Lasso motif connecting domains between TMD0 and 
TMD1 [114], specifically in a section functionally related with membrane attachment 
and transport activity [115]. R433S is located in a region close to the P-pocket 
responsible for coordination of the glutathione moiety while R1248 is positioned 
adjacent to the H-pocket containing lipid tail [114]. C1047S and R1066W are situated 
inside the cytoplasmic loop CL6 and its interaction with the 6-amino group of ATP has 
been shown to be essential for the transmission of conformational changes by ATP 
binding to the TMDs [116]. 
 
Similarly, rare variants associated with reduced survival were also found in functionally 
important regions of BCRP (encoded by ABCG2) (Fig. 10B). Contrary to MRP1, BCRP 
is a homodimer composed of two ABCG2 encoded half-transporters. T542A and 
C438R are positioned close to the translocation pore and might interfere with substrate 
translocation [117]. Q141K is located in and increase the instability of NBD, leading to 







Fig 10. Structural mapping of variants enriched in or associated with high risk group of 
the BRCA cohort. A, MRP1 consists of 2 NBDs. B, BCRP is homodimer of ABCG2-encoded protein. 
The color of the topology models was shaded according to the enrichment of deleterious variants based 
on variant effect prediction. The function domains were amplified with 3D structure with the located 
variants. All variants were additionally marked in integral tertiary structures. 
 
4.2.4 Conclusions 
Paper II studied the predictive value of genetic variability in chemoresistance related 
transporters ABCB1, ABCC1, ABCG2 on cancer chemotherapy outcome. Importantly, 
the germline variant burden of ABCC1 constituted a drug-specific biomarker of DSS 
in BRCA patients whereas no significant associations were found for individual 
variants. These findings provided a new perspective and indicated the added value of 







4.3 PAPER III: THE PREVALENCE, GENETIC COMPLEXITY AND 
POPULATION-SPECIFIC FOUNDER EFFECTS OF HUMAN AUTOSOMAL 
RECESSIVE DISORDERS 
4.3.1 Comprehensive identification of 
variants associated with human 
autosomal recessive diseases 
Overall, 508 genes causative for 450 AR 
diseases were analysed (Fig. 11). Only 
monogenic diseases with well-established 
AR inheritance pattern were included. 
Across all genes a total of 574,524 were 
identified, of which variations in low 
confidence regions and variants with 
known benign effects were excluded. 
5,188 with established pathogenicity were 
taken forward for future analyses, whereas 
the remaining 553,018 variants were 
analysed for the putative variant effects 
using an array of computational tools. 
 
Functionality of nonsense variants 
(n=22,204) was predicted using LOFTEE, 
whereas the pathogenicity of missense 
variants (n=200,633) were evaluated using 
9 partly orthogonal algorithms (see 
methods) which demonstrated the consistently best performance on missense 
pathogenicity prediction in independent datasets [97], and only those variants with 
unanimous predictions were considered as pathogenic. Combined, this workflow 
resulted in the identification of overall 46,948 putatively pathogenic variants. 
 
4.3.2 Validation of the pathogenicity prediction model 
To validate the approach for pathogenic variant selection and effect prediction, the 
estimated disease prevalence of each disease was compared with reported 
epidemiology data. Importantly, the model aligned overall well with established 
disease incidences (Pearson correlation r=0.68, p < 0.0001; Fig. 12). For instance, 
carrier rates in population-scale sequencing data allowed to accurately predict disease 
prevalence of sickle cell anemia in Africans (1 in 474 predicted vs 1 in 500 reported), 
Gaucher disease (1 in 1,019 predicted vs 1 in 750 reported), Canavan disease (1 in 
8,564 predicted vs 1 in 9,950 reported) and Tay-Sachs disease (1 in 3,864 predicted 
 





vs 1 in 3,500 reported) in Ashkenazi Jews, as well as A1AT deficiency (1 in 1,891 
predicted vs 1 in 2,500 reported) in Europeans. The model also fitted well for CF (1 in 
1,666 predicted vs 1 in 3,000 reported) in Europeans and Stargardt disease (1 in 2,333 
predicted vs 1 in 9,000 reported) in general populations. 
 
Notable outliers included type II citrullinemia, which was overestimated with reported 
incidence 1 in 165,000 and the estimated is 1 in 1,815, as well as type I tyrosinemia 
(1 in 196,167 contrasted to 1 in 16,000 reported) and AFP deficiency (1 in 2,948,001 
contrast to 1 in 105,000 
reported). Based on these 
data it was concluded that the 
in silico prediction that 
includes the computational 
prediction of rare, otherwise 
uncharacterized variants, 
overall accurately reflected the 
genetic basis for most AR 
disorders and thus constitutes 
a useful tool for the estimation 
of population-specific 
incidences for AR Mendelian 
diseases for which this 
information is not available. 
 
4.3.3 Genetic complexity of autosomal recessive disorders 
Next, the genetic complexity of the 450 investigated AR disorders was analysed. The 
informedness (see methods), defined as the maximal difference between the 
percentage of disease explained by genetic factors and the fraction of the number of 
variants used to explain pathogenicity, was employed to estimate the genetic 
complexity. This metric can evaluate the additive performance of given putatively 
pathogenic variants compared to a uniform variant allocation. As such, a higher 
informedness value indicates a higher predictive power of a selected variant panel for 
molecular disease diagnosis. 
 
Interestingly, informedness as a proxy for genetic complexity differed drastically 
between diseases, ranging from 0 to 0.96 (Fig. 13A). Congenital short bowel 
syndrome was a representative disease for high genetic complexity, as evidenced by 
a low informedness value of 0.25, indicating that the pathogenic variants underlying 
 





the disease were similarly prevalent (Fig. 13B). In contrast, CPS1 deficiency (I=0.48) 
was moderately complex, with 70% of disease incidence being explained by 23% of 
the identified pathogenic variants. Similarly in CF (I=0.69), 10% of putatively 
pathogenic variants predicted 78% disease occurrence. The least genetically complex 
disease was hemochromatosis type I (I=0.96), in which a single variant only 
(rs1800562, C282Y) explained 99% of disease cases. Across all 450 diseases 
combined, 2.2% pathogenic variants (n=1,026) were sufficient to predict 50% AR 
disease risk (Fig. 13C). 
 
The diseases were later analysed together with informedness, number of variants 
interrogated to achieve informedness, and the overall number of pathogenic variants 
for each disease. Next, it was speculated that informedness could provide a useful 
measure for genetic founder effects, as the diseases were disproportionally enriched 
in a few specific variations. Based on the analyses, 29 AR diseases were estimated 
to have strong founder effect, such as CF and Stargardt disease (Fig. 13D). These 
results align with previous reports [119,120]. 
 
The population-specific disease complexity was analysed next (Fig. 13E). The genetic 
complexity of AR diseases was overall lower in relatively isolated populations, such 
as Ashkenazi Jews and Finns, whereas complexity was markedly higher in Latinos, 
which are genetically more heterogenous. AR disorders were most genetically 
complex in Europeans, likely due to the larger sampling within Europe [31] that results 





























Fig 13. Genetic complexity of studied 450 AR disorders. A, Overview of genetic complexity 
of studied AR disorders. The higher informedness indicates lower genetic complexity of a given disease. 
B, Selected examples of differently complex diseases. C, Informedness calculated from all 450 
disorders. D, Disease complexity integrating number of pathogenic variants, informedness and 
informedness derived number of variants. E, Population-specific informedness of all 450 disorders. 
 
4.3.4 Conclusions 
Paper III systematically identified the landscape of pathogenic variants across 508 
genes associated with human AR disorders and used this extensive data set to 
estimate the genetic prevalence and complexity of 450 AR disorders. The findings 
demonstrated that population-scale sequencing data can provide a powerful resource 
for molecular disease genetics even in the absence of functional annotations. 
Furthermore, these results revealed that AR disorders differ drastically in their genetic 
constitution and population-specificity with important implications for the design of 




5 THESIS CONCLUSIONS AND FUTURE PERSPECTIVES 
5.1 CONCLUSIONS 
In summary, this PhD thesis leveraged population-scale NGS data for multiple 
applications in precision genomic medicine. Specifically, the work aspires to provide 
cases that elucidate the translational potential or different use cases in order to 
incentivize the further exploitation of the available sequencing projects in the rapidly 
evolving space of genome-guided cancer chemotherapy and carrier screening. 
 
The papers together highlighted the importance of genomics on precision medicine, 
exemplified its clinical associations in two contexts of medicine. It’s envisioned that 
more studies based on analysis of NGS projects could contribute substantially to 
precision medicine in different subareas. 
 
5.2 FUTURE PERSPECTIVES 
5.2.1 Pharmacogenomics in cancer treatment 
As described above, genetic factors account for 20-30% of interindividual differences 
in drug toxicity and response [2]. Importantly however, effects of common ABC 
transporter variants on chemotherapeutic outcomes appear to be highly context 
dependent and commonly fail to reproduce between studies, which renders them poor 
biomarkers. As such, the additional findings reported in this thesis indicate that the 
incorporation of comprehensive NGS data improves predictive models, thus 
incentivizing the transition from candidate SNP interrogations to NGS-guided 
predictions. These advances due to increased data availability is paralleled by 
developments in computational algorithms to predict the functionality of rare or novel 
variants without available experimental characterization data. Combined, in the future, 
comprehensive germline sequencing data analysed with advanced bioinformatic tools 
that allow to include the entire repertoire of genetic variation into their prediction 
models might emerge as a new strategy in precision oncology. 
 
5.2.2 Carrier screening program 
The currently established genetic carrier screening programs capture only a subset of 
disease-associated genes and even within those only a limited set of variations 
[86,121]. As such, substantial proportion of AR disease carriers remain unidentified. 
The rapid evolution of computational algorithms enables the progressively accurate 
identification of pathogenic variants of interest. Thus, it is envisioned that their 
integration with comprehensive sequencing-based approaches holds much promise 
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